6 withdrawn. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Withdrawn 6 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis Mesalamine, Placebo - Ulcerative Colitis (UC) | Phase 3 | Withdrawn | AbbVie | 2025-09-15 | 2025-08-12 | |
| SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery Aspirin 81Mg Ec Tab, Standard of Care - Crohn Disease, Ulcerative Colitis | Phase 3 | Withdrawn | Stefan Holubar MD MS FACS, FASCRS | 2024-06-01 | 2024-04-18 | |
| A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis Mirikizumab IV, Mirikizumab SC, Vedolizumab IV - Ulcerative Colitis | Phase 3 | Withdrawn | Eli Lilly and Company | 2021-04-20 | 2021-05-06 | |
| Curcumin in Pediatric Ulcerative Colitis Curcumin, Placebo - Ulcerative Colitis | Phase 3 | Withdrawn | Schneider Children's Medical Center, Israel | 2020-03-01 | 2021-10-01 | |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis Visilizumab (HuM291; Nuvion®) - Intravenous Steroid-Refractory Ulcerative Colitis | Phase 3 | Withdrawn | Facet Biotech | 150 | 2009-06-25 | |
| Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis. retarded release phosphatidylcholine - Ulcerative Colitis | Phase 2 / Phase 3 | Withdrawn | Heidelberg University | 2013-12-13 |
Colitis, Ulcerative (6) · Crohn Disease (1) · Recurrence (1) · Venous Thromboembolism (1)
Colonic Diseases (6) · Digestive System Diseases (6) · Gastroenteritis (6) · Gastrointestinal Diseases (6) · Inflammatory Bowel Diseases (6) · Intestinal Diseases (6) · Cardiovascular Diseases (1) · Disease Attributes (1) · Embolism and Thrombosis (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Thromboembolism (1) · Vascular Diseases (1)
Aspirin (1) · Curcumin (1) · Mesalamine (1) · Standard of Care (1) · mirikizumab (1) · visilizumab (1)
AbbVie (1) · Eli Lilly and Company (1) · Facet Biotech (1) · Heidelberg University (1) · Schneider Children's Medical Center, Israel (1) · Stefan Holubar MD MS FACS, FASCRS (1)
United States (2) · Germany (1) · Israel (1) · Puerto Rico (1)
Amit Assa, MD (1) · Stefan D Holubar, MD, MS (1) · Wolfgang Stremmel, Professor (1)
2019 (1)